回复：重新思考“非活动性慢性乙型肝炎”：我们是否应该治疗高HBsAg水平的患者？”

IF 25.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gut Pub Date : 2025-09-27 DOI:10.1136/gutjnl-2025-336618

Tai-Chung Tseng, Hwai-I Yang, Jia-Horng Kao

{"title":"回复：重新思考“非活动性慢性乙型肝炎”：我们是否应该治疗高HBsAg水平的患者？”","authors":"Tai-Chung Tseng, Hwai-I Yang, Jia-Horng Kao","doi":"10.1136/gutjnl-2025-336618","DOIUrl":null,"url":null,"abstract":"We appreciate the comments by Chen et al 1 on our recent publication entitled ‘Hepatitis B Surface Antigen Level Identifies Inactive Chronic Hepatitis B Patients from Asia with HCC Risk Below Surveillance Threshold’.2 Their comments highlight the heterogeneity among patients with inactive chronic hepatitis B (CHB) and raise an important clinical question: Should nucleos(t)ide analogue (NA) therapy be initiated in patients with inactive CHB with high hepatitis B surface antigen (HBsAg) levels? First, among the 58 patients with hepatocellular carcinoma (HCC) with baseline HBsAg >100 IU/mL, 27 (46.6%) had hepatitis B virus (HBV) DNA levels <200 IU/mL. Baseline HBV DNA levels were not associated with HCC development in patients with inactive CHB (table 2 of the original article). Given this, we questioned whether viral rebound, rather than baseline viral …","PeriodicalId":12825,"journal":{"name":"Gut","volume":"2 1","pages":""},"PeriodicalIF":25.8000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to: ‘Rethinking “inactive chronic hepatitis B”: should we treat patients with high HBsAg levels?’\",\"authors\":\"Tai-Chung Tseng, Hwai-I Yang, Jia-Horng Kao\",\"doi\":\"10.1136/gutjnl-2025-336618\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We appreciate the comments by Chen et al 1 on our recent publication entitled ‘Hepatitis B Surface Antigen Level Identifies Inactive Chronic Hepatitis B Patients from Asia with HCC Risk Below Surveillance Threshold’.2 Their comments highlight the heterogeneity among patients with inactive chronic hepatitis B (CHB) and raise an important clinical question: Should nucleos(t)ide analogue (NA) therapy be initiated in patients with inactive CHB with high hepatitis B surface antigen (HBsAg) levels? First, among the 58 patients with hepatocellular carcinoma (HCC) with baseline HBsAg >100 IU/mL, 27 (46.6%) had hepatitis B virus (HBV) DNA levels <200 IU/mL. Baseline HBV DNA levels were not associated with HCC development in patients with inactive CHB (table 2 of the original article). Given this, we questioned whether viral rebound, rather than baseline viral …\",\"PeriodicalId\":12825,\"journal\":{\"name\":\"Gut\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":25.8000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gut\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/gutjnl-2025-336618\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/gutjnl-2025-336618","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们感谢Chen等人对我们最近发表的题为“乙型肝炎表面抗原水平确定亚洲非活动性慢性乙型肝炎患者HCC风险低于监测阈值”的评论他们的评论强调了非活动性慢性乙型肝炎（CHB）患者之间的异质性，并提出了一个重要的临床问题：是否应该在高乙型肝炎表面抗原（HBsAg）水平的非活动性慢性乙型肝炎患者中开始核苷(t)类似物（NA）治疗？首先，在58例基线HBsAg为100 IU/mL的肝细胞癌（HCC）患者中，27例（46.6%）乙型肝炎病毒（HBV） DNA水平<200 IU/mL。基线HBV DNA水平与非活动性CHB患者的HCC发展无关（原始文章的表2）。鉴于此，我们质疑病毒反弹，而不是基线病毒…

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Reply to: ‘Rethinking “inactive chronic hepatitis B”: should we treat patients with high HBsAg levels?’

We appreciate the comments by Chen et al 1 on our recent publication entitled ‘Hepatitis B Surface Antigen Level Identifies Inactive Chronic Hepatitis B Patients from Asia with HCC Risk Below Surveillance Threshold’.2 Their comments highlight the heterogeneity among patients with inactive chronic hepatitis B (CHB) and raise an important clinical question: Should nucleos(t)ide analogue (NA) therapy be initiated in patients with inactive CHB with high hepatitis B surface antigen (HBsAg) levels? First, among the 58 patients with hepatocellular carcinoma (HCC) with baseline HBsAg >100 IU/mL, 27 (46.6%) had hepatitis B virus (HBV) DNA levels <200 IU/mL. Baseline HBV DNA levels were not associated with HCC development in patients with inactive CHB (table 2 of the original article). Given this, we questioned whether viral rebound, rather than baseline viral …

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Gut 医学-胃肠肝病学

CiteScore

45.70

自引率

2.40%

发文量

284

审稿时长

1.5 months

期刊介绍： Gut is a renowned international journal specializing in gastroenterology and hepatology, known for its high-quality clinical research covering the alimentary tract, liver, biliary tree, and pancreas. It offers authoritative and current coverage across all aspects of gastroenterology and hepatology, featuring articles on emerging disease mechanisms and innovative diagnostic and therapeutic approaches authored by leading experts. As the flagship journal of BMJ's gastroenterology portfolio, Gut is accompanied by two companion journals: Frontline Gastroenterology, focusing on education and practice-oriented papers, and BMJ Open Gastroenterology for open access original research.